PepGen presents an overview of its enhanced delivery oligonucleotide platform and how this innovative platform technology is being applied to create a transformative exon skipping therapy. James McArthur, CEO of PepGen discusses the technology with the community and plans for next stages of development.
James McArthur, CEO of PepGen has 25+ years of industry experience, has co-founded 5 biotechnology companies, 3 of which were acquired and been a director of two companies that went public. He was founding CEO of Imara, a public company developing therapies for sickle cell disease and b-thallasemia, co-founder and President of R&D of Cydan a rare disease accelerator and founding CSO of Synovex/Adheron, a rheumatology therapy company acquired by Roche. Prior to these companies, James held senior research leadership roles in several pioneering gene and stem cell therapy companies. He is a Venture Partner at RA Capital and was an entrepreneur in residence at HealthCare Ventures. James was a post-doctoral fellow at MIT and UC Berkeley working with Drs. David Raulet and Nobel Laureate James Allison, before which, he received his PhD in molecular oncology and BSc in biochemistry from McGill University in Montreal.
You’ll be prompted to enter your name and email address to view the recording.